Resize text 
Resize text
The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) has from the outset aimed to be inclusive of expertise in relevant scientific fields. Given the rate at which the network has expanded, it has been decided to foster the development of new networks within the network based around a shared interest in particular topics. The role of these 'special interest groups’ (SIGs) will be to lead and advise the ENCePP Steering Group, where applicable, on future activities of ENCePP. This should enable to better focus and progress discussions on topic-related issues, thus expediting the generation of specific outputs.
The following SIGs are currently active:
A key task for the SIG is to regularly review the “Overview of data sources for drug safety in pregnancy research” that was developed by the University of Bath as a deliverable of an EMA funded study on the safety of A/H1N1 vaccines in pregnant women.
Related information:
The mandate of the ENCePP SIG on Impact is to provide recommendations (e.g. in form of guidance documents or publications in peer-reviewed journals) to the PRAC Interest Group (IG) on Impact on the key methodologies for measuring health outcomes of pharmacovigilance activities which contribute to the overall evaluation of the impact of pharmacovigilance systems in line with the PRAC Strategy on Measuring the Impact of Pharmacovigilance Activities.
Related information:
For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
